| scholarly article | Q13442814 |
| P2093 | author name string | Jun Wang | |
| Yan Guo | |||
| Baocheng Wang | |||
| Huili Chu | |||
| Jianpeng Chen | |||
| P2860 | cites work | A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. | Q54621891 |
| Tumor angiogenesis and biologic markers in resected stage I NSCLC | Q59219583 | ||
| Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study | Q59219589 | ||
| A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer | Q60362076 | ||
| China offers alternative gateway for experimental drugs | Q82498045 | ||
| Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) | Q83523403 | ||
| A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer | Q84007306 | ||
| Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial | Q84078521 | ||
| PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage | Q86564392 | ||
| Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study | Q87056653 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations | Q26744339 | ||
| Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer | Q26824059 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial | Q27853359 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Q29620648 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. | Q30664849 | ||
| Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer | Q33384457 | ||
| Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer | Q33400988 | ||
| First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients | Q33401434 | ||
| A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). | Q33408559 | ||
| PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s | Q33418542 | ||
| Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer | Q33418595 | ||
| Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer | Q33598561 | ||
| Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. | Q33710574 | ||
| Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer | Q33817062 | ||
| Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer | Q33901988 | ||
| Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial | Q34050239 | ||
| A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer | Q34194044 | ||
| International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. | Q34285538 | ||
| Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). | Q34303927 | ||
| A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528 | Q34322552 | ||
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 | ||
| BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q39746785 | ||
| Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors | Q39961300 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy | Q40561716 | ||
| EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer | Q40562646 | ||
| Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. | Q40657525 | ||
| Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) | Q42073978 | ||
| Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer | Q42632045 | ||
| An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer | Q42635935 | ||
| Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. | Q42669075 | ||
| Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. | Q43138109 | ||
| Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer | Q43299264 | ||
| Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatme | Q43790301 | ||
| Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). | Q43906269 | ||
| A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). | Q43943343 | ||
| Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. | Q44358969 | ||
| Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer | Q44915586 | ||
| ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. | Q45930549 | ||
| Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy | Q46079896 | ||
| Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer | Q46308248 | ||
| Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial | Q46684151 | ||
| Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer | Q46972019 | ||
| Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. | Q48084391 | ||
| Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study | Q48883337 | ||
| Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. | Q50451474 | ||
| Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cance | Q51299587 | ||
| BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer | Q51628000 | ||
| Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer | Q52840654 | ||
| Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial | Q53124033 | ||
| Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. | Q54410290 | ||
| Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer | Q54616228 | ||
| Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. | Q34458617 | ||
| Comparing antibody and small-molecule therapies for cancer | Q34560075 | ||
| Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial | Q34658812 | ||
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | Q34662482 | ||
| Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl | Q34669325 | ||
| CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer | Q34836398 | ||
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil | Q34935734 | ||
| Bevacizumab plus ipilimumab in patients with metastatic melanoma | Q35012765 | ||
| VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors | Q35064894 | ||
| Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial | Q35576189 | ||
| Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network | Q35584533 | ||
| Antiangiogenic therapy and tumor progression | Q35641618 | ||
| A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. | Q36241287 | ||
| Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer | Q36455063 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In | Q37132598 | ||
| VEGFs and receptors involved in angiogenesis versus lymphangiogenesis | Q37397202 | ||
| Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study | Q37633813 | ||
| Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis | Q37850174 | ||
| Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC) | Q37852264 | ||
| Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer | Q37877518 | ||
| Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? | Q38000486 | ||
| Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer | Q38062459 | ||
| Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better…. | Q38160072 | ||
| Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study | Q38245038 | ||
| Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lun | Q38382765 | ||
| MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens | Q38383649 | ||
| New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer | Q38556297 | ||
| Anti-angiogenesis in Personalized Therapy of Lung Cancer | Q38669276 | ||
| Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
| The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. | Q38978231 | ||
| Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial | Q39042041 | ||
| Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo | Q39163764 | ||
| Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients | Q39363137 | ||
| Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer | Q39576387 | ||
| P433 | issue | 32 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 53854-53872 | |
| P577 | publication date | 2017-05-17 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Strategies targeting angiogenesis in advanced non-small cell lung cancer | |
| P478 | volume | 8 |
| Q59794392 | Q59794392 |
| Q47326502 | ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT. |
| Q48507616 | Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice |
| Q90169736 | Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect via Multi-functional Nanoparticles for Orthotopic Non-Small Cell Lung Cancer Treatment |
| Q58770914 | Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer |
| Q52661758 | Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma |
| Q90087598 | Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer |
| Q47093979 | Gendermetrics of cancer research: results from a global analysis on lung cancer |
| Q55224564 | High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer. |
| Q90762243 | Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer |
| Q90300758 | Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer |
| Q89741649 | New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer |
| Q57491166 | Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC |
| Q97520423 | Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies |
| Q58750993 | SOX5 induces lung adenocarcinoma angiogenesis by inducing the expression of VEGF through STAT3 signaling |
| Q51740041 | Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells |
| Q56956755 | TIE2-expressing monocytes and M2-polarized macrophages impact survival and correlate with angiogenesis in adenocarcinoma of the pancreas |
| Q50052820 | Targeted drugs for systemic therapy of lung cancer with brain metastases |
| Q55008337 | Targeting VEGF/VEGFR to Modulate Antitumor Immunity. |
| Q91828595 | The Biological-Behavioral Effect Of Neuritin On Non-Small Cell Lung Cancer Vascular Endothelial Cells Via VEGFR And Notch1 |
| Q90643245 | The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients |
| Q47205727 | The fibrotic tumor stroma |
Search more.